FDA puts AstraZeneca’s camizestrant decision on hold after panel flags limited benefit
TL;DR
The FDA postponed its decision on AstraZeneca’s oral breast cancer drug camizestrant after an advisory committee voted (6-3) that the treatment did not show a clinically meaningful benefit in the Serena-6 switching trial. AstraZeneca provided additional analyses requested by the agency, including circulating tumor DNA data, and the FDA is reviewing them before issuing a ruling; no new decision date has been set. Europe has given a positive opinion for camizestrant, which will be marketed as Etcamah there.
- FDA delays ruling on AstraZeneca drug after negative adcomm vote Fierce Biotech
- US regulator delays decision on AstraZeneca cancer drug Financial Times
- Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm Fierce Pharma
- Pharmalittle: We're reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more statnews.com
- AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data The Independent
Want the full story? Read the original reporting
Read on Fierce Biotech